Bioasis Technologies Inc. (BIOAF)
- Previous Close
0.0060 - Open
0.0060 - Bid --
- Ask --
- Day's Range
0.0060 - 0.0060 - 52 Week Range
0.0020 - 0.0180 - Volume
10,000 - Avg. Volume
16,196 - Market Cap (intraday)
476,484 - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.
www.bioasis.usRecent News: BIOAF
Performance Overview: BIOAF
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIOAF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIOAF
Valuation Measures
Market Cap
288.98k
Enterprise Value
1.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.30
Price/Book (mrq)
--
Enterprise Value/Revenue
6.63
Enterprise Value/EBITDA
-0.57
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-80.58%
Return on Equity (ttm)
--
Revenue (ttm)
269.38k
Net Income Avi to Common (ttm)
-2.88M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
156.51k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-310.48k
Research Analysis: BIOAF
Company Insights: BIOAF
BIOAF does not have Company Insights